Media.Player

EAF1 and EAF2 Mouse Monoclonal Antibodies

Detailed Technology Description

None

*Abstract

BackgroundEAF proteins are potential tumor suppressors and play a major role in prostate cancer progression. In more than 80 % of advanced human prostate cancer specimens there is EAF2 down regulation and loss of heterozygosity . This is a clear indica-tion that EAF2 likely blocks prostate cancer pro-gression. Following this studies have shown that an overexpression of EAF2 induces apoptosis in prostate cancer cell lines, both in-vitro and in -vivo, while EAF2 gene knockout in mice resulted in multiple tissue tumors. With this property of EAF2 , it is vital that there exists an antibody that captures the endogenous expression levels .TechnologyDr. Wang and colleagues have developed novel EAF1 and EAF2 antibodies that can recognize the antigen in the native and denatured form with higher specificity than antibodies that are commercially available.Application Anti-EAF1 1. Incorporation in western blotting protocols 2. Efficient for ELISA and IP 3.Efficient for IHC staining of transfected EAF1 in cell block Anti-EAF2 1. Incorporation in IHC and western blotting protocols 2. Efficient for ELISA and IPAdvantages1. Recognizes endogenous and transfected proteins in human prostate tissue specimens and cell lines. 2. Identifies human EAF1 and EAF2 proteins 3. Efficient against the native and denatured protein statesStage of Development Efficacy of the antibody was tested in-vitro using cell lines and human tissue samples. Hybridoma cell lines secreting EAF1 and U19/EAF2 specific monoclonal antibdies have been generated.

*Principal Investigator

Name: Junkui Ai

Department: Med-Urology

Name: Soldano Ferrone, Professor

Department: Department of Surgery

Name: Xinhui Wang, Assistant Professor

Department: Med-Immunology

Name: Zhou Wang

Department: Med-Urology

Country/Region

USA